CD33 and acute myeloid leukemia: GO received accelerated approval in 2000 as a single agent at a dose of 9 mg/m2 per day (days 1 and 14) to treat patients with CD33 + AML in their first relapse who were 60 years of age or older and who were not considered for cytotoxic chemotherapy.